Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells + secretome
- Development stage
- Unknown
- Lead developer
- Prodia Stem Cell Indonesia
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intranasal
01
Overview
Umbilical cord-derived mesenchymal stem cells + secretome is a combination cell therapy and biologic product developed by PT. Prodia Stem Cell Indonesia. It is currently being investigated as an adjuvant treatment for patients suffering from severe acute respiratory distress syndrome (ARDS) and sepsis secondary to pneumonia. The therapy utilizes the immunomodulatory and regenerative properties of umbilical cord-derived mesenchymal stem cells (UC-MSCs), administered intravenously, in conjunction with the intranasal administration of the MSC-derived secretome. The secretome contains a concentrated mixture of bioactive paracrine factors, including cytokines and growth factors, intended to modulate the inflammatory environment in the lungs and promote tissue repair. This dual approach aims to reduce systemic inflammation and localized pulmonary damage, thereby decreasing mortality and shortening hospital stays for critically ill patients.
- Other names
- UC-MSC and SecretomeUC-MSC + Secretome
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells + secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells + secretome.